RecruitingOBSERVATIONAL

Cisplatin Induced Kidney Toxicity

Cisplatin is a very effective chemotherapy drug used for many cancers, but it can harm the kidneys. This kidney damage, called acute kidney injury (AKI), can cause serious problems for patients. Currently, AKI is only found after damage has already occurred, making it hard to prevent or treat effectively. This study uses a special technique called metabolomics to look for tiny molecules in blood and urine. These molecules can act as early warning signals. By studying these signals in adults and children receiving Cisplatin, we hope to find ways to predict who is at risk of kidney damage before treatment, and detect it very early on. This could allow doctors to adjust treatment, prevent complications, and improve overall health outcomes for patients.

At a glance

Status

Recruiting

Sponsor

The Hospital for Sick Children

Enrolment target

600

Start

12 Aug 2020

Estimated completion

31 Dec 2028

Acute Kidney Injury Cancer

What is this study about?

Cisplatin is a powerful chemotherapy drug that helps fight various cancers, including those in the head, neck, and lungs in adults, and over 15 types of childhood cancers. It's often doctors' first choice because it works so well. However, a significant side effect is kidney damage, known as acute kidney injury (AKI), which affects 20-50% of patients. This usually happens within a few days of treatment and can lead to both short-term and long-term health problems. The biggest challenge is that doctors can only diagnose AKI once the kidneys are already significantly damaged, and by then, it's often too late to prevent further issues.

Imagine if we could know ahead of time who might be at risk, or detect kidney damage much earlier, before it becomes a serious problem. That's exactly what this study aims to do. We're exploring a new approach called 'metabolomics,' which involves identifying patterns of tiny molecules, called metabolites, in your body. These molecules are linked to how your cells and tissues are working and can show changes related to diseases or even your lifestyle. Blood and urine are perfect for checking these metabolites because they can reveal signs of trouble earlier than current tests.

Researchers in Canada will collect blood and urine samples from adults and children who are receiving Cisplatin treatment. We'll look for specific metabolite patterns: some before Cisplatin is given, to predict who might be at higher risk of kidney damage, and others shortly after treatment, to catch early signs of kidney injury before any obvious symptoms appear. The goal is that finding these early warning signs will allow doctors to tailor Cisplatin treatment to each patient, reducing the risk of kidney problems and improving their journey to recovery.

Key takeaways

Cisplatin is an important cancer drug, but it can harm the kidneys.
This study aims to find early warning signs of kidney damage before symptoms appear.
Researchers will look at blood and urine samples for special molecules called metabolites.
The goal is to personalize treatment and help prevent kidney problems for cancer patients.
Participation will help future patients avoid serious treatment side effects.

Who may be eligible?

To join this study, adult participants must be starting Cisplatin treatment for head, neck, or lung cancer, and be 18 years or older. For children, they need to be over 3 months old and starting Cisplatin for any type of cancer.

However, there are some reasons why someone might not be able to join. This includes if you already have a diagnosed long-term kidney condition, or if you've recently taken other medications that can be harmful to the kidneys in the last two weeks. Also, if you've had Cisplatin before, or certain types of radiation treatment or stem cell transplants recently, you wouldn't be able to participate.

Ultimately, your doctor will decide if this study is right for you, taking into account any other health conditions you might have, such as heart, lung, liver, or ongoing infections, to ensure your safety and that the study is a good fit.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you an adult starting Cisplatin for head/neck or lung cancer, or a child over 3 months old starting Cisplatin for any cancer?
Have you been diagnosed with a long-term kidney disease?
Have you taken other kidney-damaging medicines in the last two weeks?
Have you had Cisplatin treatment before?
Have you had certain types of radiation or a stem cell transplant recently?

Answer every question to see your result.

What does participation involve?

If you decide to take part, you'll be asked to complete a questionnaire about your health. We will also collect samples of your blood, urine, and saliva. The exact number of samples and when they are collected will depend on your treatment schedule. However, these will be timed around your Cisplatin doses. There are no new medications for this study; you will only receive your standard Cisplatin chemotherapy as prescribed by your doctor. The study will follow you through your course of Cisplatin treatment and will involve several collection points to get samples before, during, and after your chemotherapy doses. The total duration of your participation will depend on how long you receive Cisplatin, but could last several months.

Potential risks and benefits

Participating in this study might not directly benefit your health immediately, as the aim is to discover new information for future patients. However, you would be contributing significantly to medical research, helping us understand and potentially prevent a serious side effect of cancer treatment for many others. The main risks involved are those typically associated with blood, urine, and saliva collection, such as minor discomfort or bruising from blood draws. There's also the chance that the information gathered might not be useful. Remember, your participation is completely voluntary, and you are free to withdraw from the study at any time without affecting your medical care.

Locations (1)

London Health Sciences Centre
Verified postcode
London, Canada· Recruiting

Common questions

What is Cisplatin?

Cisplatin is a strong chemotherapy drug used to treat many types of cancer in both adults and children.

What is 'kidney toxicity'?

Kidney toxicity means damage to the kidneys. In this study, we're looking at damage that can be caused by the drug Cisplatin.

What is 'Acute Kidney Injury' (AKI)?

AKI is when your kidneys suddenly stop working as well as they should, often within a few days. If not caught early, it can lead to serious health problems.

What are 'metabolites'?

Metabolites are tiny molecules in your body that can tell us a lot about how your cells are working and if there are any disease processes happening.

Will I get an extra drug for this study?

No, you will only receive the standard Cisplatin treatment prescribed by your doctor. This study doesn't involve any new or experimental medications.

How to find out more

Michael Zappitelli, MD

michael.zappitelli@sickkids.ca 416-813-7654 Official trial record

Always speak to your GP or specialist before deciding to take part in a study.